Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ophthalmology
Biotech
China-based biotech plans ph. 3 after seeing midstage eye data
Minghui Pharmaceutical has linked its novel thyroid eye disease treatment to a reduction in eye bulging in a phase 1b/2 clinical trial.
Gabrielle Masson
Oct 22, 2024 10:37am
Phase 2 fail sends OcuTerra's eye drop dreams down the drain
Mar 14, 2024 9:15am
Eyconis launches with $150M and Ascendis' eye disease meds
Jan 29, 2024 11:03am
iuvo BioScience acquires ophthalmology CRO Promedica
Jan 24, 2024 9:49am
Zeiss offers €985M to acquire fellow ophthalmic devicemaker
Dec 18, 2023 10:05am
Zeiss, Boehringer eye retinal disease-focused predictive AI pact
Oct 2, 2023 1:00pm
